Skip to main content

Table 2 Univariate and multivariate models for chemotherapy-free survival in gastric cancer patients who underwent chemotherapy in The Cancer Genome Atlas (TCGA)

From: Somatic mutation of DNAH genes implicated higher chemotherapy response rate in gastric adenocarcinoma patients

Characteristic Univariate analysis Multivariate analysis
HR (95% CI) P value HR (95% CI) P value
Chemotherapy-free survival
 DNAH status 0.456 (0.248–0.848) 0.011 0.446 (0.233–0.856) 0.015
 TNM stage 1.767 (1.010–3.092) 0.046 1.275 (0.716–2.268) 0.409
 R0 resection 5.780 (2.464–13.558) < 0.001 5.289 (2.097–13.341) < 0.001
 Grade 1.327 (0.722–2.439) 0.361   
 Age at diagnosis, y 1.010 (0.982–1.308) 0.482   
Fluoropyrimidine-free survival
 DNAH status 0.518 (0.264–0.014) 0.055   
 TNM stage 1.485 (1.189–5.192) 0.016 2.080 (0.961–4.502) 0.063
 R0 resection 6.295 (2.338–16.963) < 0.001 5.136 (1.848–14.275) 0.002
 Grade 1.429 (0.794–2.575) 0.234   
 Age at diagnosis, y 1.019 (0.986–1.053) 0.269   
Platinum-free survival
 DNAH status 0.217 (0.061–0.768) 0.018 0.137 (0.030–0.629) 0.011
 TNM stage 1.716 (0.761–3.872) 0.193   
 R0 resection 4.184 (1.172–14.932) 0.027 5.116 (1.415–18.501) 0.013
 Grade 1.415 (0.454–4.411) 0.550   
 Age at diagnosis, y 1.000 (0.959–1.044) 0.988   
  1. Statistically significant values are in italics